The prevalence of diabetes mellitus is increasing at a dramatic rate, and countries in Asia, particularly India and China, will bear the brunt of this epidemic. Persons with diabetes have a significantly increased risk of active tuberculosis (TB), which is two to three times higher than in persons without diabetes. In this article, we argue that the epidemiological interactions and the effects on clinical presentation and treatment resulting from the interaction between diabetes and TB are similar to those observed for human immunodeficiency virus (HIV) and TB. The lessons learned from approaches to reduce the dual burden of HIV and TB, and especially the modes of screening for the two diseases, can be adapted and applied to the screening, diagnosis, treatment and prevention of diabetes and TB. The new World Health Organization (WHO) and The Union Collaborative Framework for care and control of TB and diabetes has many similarities to the WHO Policy on Collaborative Activities to reduce the dual burden of TB and HIV, and aims to guide policy makers and implementers on how to move forward and combat this looming dual epidemic. The response to the growing HIV-associated TB epidemic in the 1980s and 1990s was slow and uncoordinated, despite clearly articulated warnings about the scale of the forthcoming problem. We must not make the same mistake with diabetes and TB. The Framework provides a template for action, and it is now up to donors, policy makers and implementers to apply the recommendations in the field and to 'learn by doing'.
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-Samuel Johnson WHEN the acquired immune-defi ciency syndrome (AIDS) was fi rst reported in 1981, there was little realisation at the time of the impending scale of the forthcoming epidemic or that the epicentre would be in sub-Saharan Africa. Thirty years on, the statistics make grim reading: 60 million infections, more than 25 million deaths and more than 33 million persons currently living with human immunodefi ciency virus (HIV) infection or AIDS. 1 Sub-Saharan Africa has borne the brunt of this epidemic: the latest estimates are that 22.5 million persons are living with HIV/ AIDS, of whom an estimated 50% live in southern Africa. 2 In 2009, about one third of all persons living with HIV (PLWH), one third of all new infections and one third of all AIDS-related deaths occurred in just 10 countries in southern Africa. 2 Chronic, non-communicable diseases such as c ardiovascular disease, diabetes mellitus (DM), cancer and chronic obstructive pulmonary disease have insidiously emerged as the next twenty-fi rst century global epidemic. These diseases have become the leading causes of death and disability worldwide, and are predicted to be the cause of over three quarters of global deaths by 2030. 3 In parts of rural Africa, there is already an epidemiological transition, with chronic
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The looming diabetes-TB epidemic 1437 care illness as a result of communicable (HIV/AIDS) and non-communicable diseases contributing more to mortality than acute care illness. 4 The fact that chronic diseases are becoming increasingly important in the setting of economic development and a threat to health in low-and middle-income countries has been recognised by the United Nations General Assembly, and a high-level meeting with the participation of heads of state is to be hosted on the topic in September 2011. 5 Tuberculosis (TB) emerged early in the HIV epidemic as one of the most important and serious opportunistic infections to be associated with HIV, and has become the leading cause of death in HIV-infected persons. 6 Nowhere is this more starkly apparent than in sub-Saharan Africa, where HIV has been responsible for an unprecedented increase in TB case notifi cations and for derailing TB control efforts. 7 In this article, we argue that there is an important interaction between DM and TB, the effects of which may be similar to those observed between HIV and TB. Although at the individual level the risk of developing TB is considerably lower in persons with DM than in HIV patients, the much larger, and rapidly growing, pool of DM patients makes the global and population attributable fraction of TB due to DM very similar to that seen with HIV. 8 We believe that DM-associated TB is the next looming challenge for global TB control, with the battleground being focused in Asia, and particularly India and China. We compare and contrast the interactions, interventions and framework for collaborative activities between HIV and TB and DM and TB, and believe that if we are forewarned and prepared we stand a better chance of reducing the dual burden of disease of DM and TB than was the case with HIV and TB.
THE DIABETES EPIDEMIC
According to a global analysis involving 199 countries and 2.7 million persons, the number of adults with DM increased alarmingly from 153 million in 1980 to 347 million in 2008. 9 Numbers are predicted to rise to 472 million by 2030, with almost 80% of DM patients living in low-and middle-income countries. 10 Although much of this increase in DM is attributed to population growth and aging, it also refl ects a global shift towards a western lifestyle of unhealthy eating and physical inactivity.
Although this is a global epidemic, Asia is the epicentre of the escalating burden of disease. 9, 11 Estimates based on population growth, aging and urbanisation indicate that India and China are, and will be, the two countries with the highest numbers of DM patients: the 199-country analysis estimated that 40% of DM patients (138 million in 2008) live in China and India. Among the next top eight countries, four more are in Asia: Indonesia, Pakistan, Bangladesh and the Philippines. 11 As with HIV/AIDS in the early years, the scale of the epidemic is probably underestimated. A national representative survey in China involving over 46 000 adults between 2007 and 2008 showed, when extrapolated to the total population, that an estimated 92 million adults had DM, in contrast to a previous estimation of approximately 42 million. 12 Of note, and similar to the global situation with HIV, is the observation that in over 60% of adults with DM in China, the disease was undiagnosed at the time of the survey. 12 Morbidity and mortality accompany this rise in case burden. A hospital-based study in China, for example, showed that more than half of persons with known DM experience chronic complications and exhibit poor glucose control. 13 In 2010, there were an estimated 3.5 million deaths due to DM worldwide. 14 
EPIDEMIOLOGICAL INTERACTIONS BETWEEN HIV, DM AND TB
From the mid-1980s, TB programmes in countries with high HIV prevalence rates, particularly in subSaharan Africa, saw rising TB case notifi cations, and over a period of 10-15 years these increased up to 500% in some countries. A number of recent literature reviews, which have included systematic reviews and meta-analyses of previous studies, have shown that DM patients have a signifi cantly increased risk of developing active TB, which is two to three times higher than in persons without DM. [15] [16] [17] [18] Previous studies have tended to be secondary analyses of usually health facility-based data, and are subject to confounding and other limitations. Nevertheless, there has been a consistency in the fi ndings, and prospective studies are currently underway. On the TexasMexico border, for example, it was shown prospectively that DM contributed 25% of TB cases, whereas HIV infection contributed ⩽5%. 19 To date, little information has been published on whether DM has any effect on TB case notifi cations or estimated case numbers at country level. However, an ecological association between changes in DM and TB prevalence has been observed across 46 countries. 20 Furthermore, an analysis of nutrition and DM changes in I ndia suggests that increased DM prevalence between 1998 and 2008 contributed to an increase in the total number of TB cases, which exceeded the rate of population growth in the same time period. 21 It will be important to further focus on and monitor this association, especially in countries in Asia with escalating DM epidemics.
MECHANISMS OF ASSOCIATION BETWEEN HIV, DM AND TB
HIV causes disease by destroying cells of the immune system, with the gradual decrease and dysfunction of naive and memory CD4+ T-lymphocyte populations (which control the body's defences against infection) being the hallmark of infection. 22 The association between HIV and TB stems from two distinct processes: HIV increases the risk of reactivation in those who already have latent TB infection by up to 100 times; in those who acquire new TB infection, HIV increases the risk of progression to active disease. 7 While the risk of active TB in an individual is related to the prevailing socio-economic conditions and pressure of exogenous TB infection in the community, the critical determinant is the degree of immunodefi ciency, as measured by the CD4-lymphocyte count, with the lower counts and the amount of time accrued at low counts being signifi cantly associated with increasing risk of TB. 23 DM increases the general risk of infection, but the precise mechanisms by which DM predisposes to TB are still not clear. DM does not reduce CD4+ Tlymphocyte populations, but rather impairs the function and activation of macrophages, monocytes and lymphocytes which play a pivotal role in combating the TB pathogen. 15, 17, 24, 25 The relative contribution of other factors such as pulmonary microangiopathy, renal dysfunction and vitamin defi ciencies remains to be established. 15 DM patients with poorer glycaemic control appear to be at higher risk for TB, 26, 27 demonstrating a dose-response relationship between the degree and duration of hyperglycaemia and vulnerability to TB, rather similar to that observed with HIV and TB.
EFFECT ON CLINICAL MANIFESTATIONS OF TB BY HIV AND DM
In PLWH, the clinical pattern of TB correlates with the host immune status. As the immune system becomes more compromised, granuloma formation decreases and the pattern of TB shifts from typical sputum smear-positive, cavitary, upper-lobe pulmonary disease to atypical smear-negative, infi ltrative, lowerlobe pulmonary disease or extra-pulmonary disseminated disease. As CD4-counts decline to levels below 100 cells/μl, the proportions of PLWH with cultureconfi rmed pulmonary TB who have negative sputum smears, who are without radiographic cavities and who have normal chest radiographs, increase. 28 A similar, although not always consistent, picture may be found in DM patients. 17 Nearly 90 years ago, it was reported that a large proportion of DM patients had lower lung involvement, in contrast to non-DM patients, who usually had upper lobe infi ltrates. 29 While the predominance of lower-lobe infi ltrates in DM patients has been confi rmed in more recent studies, 30 ,31 these fi ndings are not consistent, 17, 32 and higher quality, prospective research in this area is needed. As is the case with HIV, it is likely that clinical and radiographic manifestations of TB are a feature of host immune status, and poorly controlled DM patients with hyperglycaemia may have a higher frequency of atypical features of TB.
ANTI-TUBERCULOSIS TREATMENT AND EFFECT ON TREATMENT OUTCOMES BY HIV AND DM
International guidelines disseminated by the World Health Organization (WHO) recommend that treatment for TB be standardised with 6-month rifampicin (RMP) based regimens. 33 TB patients who are HIVinfected should receive anti-tuberculosis treatment of the same duration as HIV-negative TB patients. 33 However, in industrialised countries, the optimal duration of treatment for HIV-infected TB patients is still controversial. For example, in the United States it is recommended that 6-month regimens be given, but this should be extended by 3 months if the patient presents with cavitary lung disease or is still sputum culture positive for Mycobacterium tuberculosis 2 months after the start of treatment. 34 In DM patients, the same recommendations for a standardised 6-month anti-tuberculosis regimen apply, although clinicians in industrialised countries may take a more individualised approach and consider the possibility of longer treatment as a result of the associated immune dysfunction. 35 Whether longer treatment in TB patients with DM has a benefi cial effect on treatment outcomes and in reducing the risk of recurrent disease is not known and needs prospective research. 36 PLWH respond as well to anti-tuberculosis treatment as non-HIV-infected patients, with similar rates of sputum conversion and radiographic improvement. However, there are two major problems: in the absence of cotrimoxazole adjunctive therapy or antiretroviral therapy (ART), TB case-fatality rates are high, and are related, in sub-Saharan Africa at least, to the degree of HIV-related immune suppression. 37 If a patient completes treatment satisfactorily, the rates of recurrent TB are much higher in HIV-infected than in HIV-negative patients. 38, 39 Low initial CD4 counts are a risk factor for recurrence, 39 with most second episodes of TB being a result of re-infection with a new strain of M. tuberculosis. 40 Standard anti-tuberculosis treatment on its own is not enough to reduce TB case fatality or recurrence. 41 Interventions for both of these adverse events require timely initiation of cotrimoxazole preventive therapy, ART and consideration of secondary isoniazid (INH) prophylaxis. 42 DM appears to have a similar effect on treatment outcomes (Table 1) . A systematic review of studies, papers and reports from 1980 to December 2010 assessed the results of sputum culture conversion at 2-3 months of anti-tuberculosis treatment, death during treatment and relapse of TB after successful completion of treatment. 43 Nine studies analysed culture positivity at 2-3 months of treatment, with six reporting relative risks of >2, and three reporting relative risks of <1. 43 However, all but one of the studies reported a delay in sputum culture conversion at some point during the course of anti-tuberculosis treatment. A total of 23 studies assessed risk of death during TB treatment, with a pooled and signifi cantly higher relative risk of 1.89 in DM patients. 43 Four of these studies adjusted for age and other potential confounders, fi nding a pooled odds ratio of 4.95; this suggests that patients who die during anti-tuberculosis treatment have other strong risk factors for death, such as HIV and comorbidities, which reduce the impact of DM in unadjusted analyses. Five studies assessed the risk of TB relapse, with a pooled and increased signifi cant relative risk of 3.89 in DM patients. 43 Whether these patients experienced a recurrence of the former infection (true relapse) or re-infection with a new strain of M. tuberculosis is not known.
There are many unanswered questions, including the infl uence of poor DM control on death and recurrent TB, the timing and aetiology of death in DM patients, the reasons for recurrent disease, and interventions that may reduce the frequency of these adverse events. These questions are best answered through prospective rather than retrospective studies. DM impairs innate and adaptive immune responses, and poor DM control, as measured by glycosylated haemoglobin (HbA 1c ) levels, affects in vitro innate and cellmediated immune cytokine responses. 44 TB disease per se and the drugs used to treat TB, such as RMP, can all worsen DM control, particularly the use of RMP as a result of direct and indirect interactions with oral hypoglycaemic drugs. 45 Uncontrolled DM can eventually lead to impaired renal function and an increased risk of drug toxicities. Hepatic toxicity due to anti-tuberculosis drugs may also be increased in DM patients, potentially increasing the risk of adverse treatment outcomes. 46 
SCREENING TB PATIENTS FOR HIV AND DM AND REFERRAL TO CARE
The crucial fi rst step for ensuring access to HIV prevention and care in TB patients in high TB-HIV burden countries is to ensure that they are counselled and tested for HIV. The WHO recommends that provider-initiated HIV testing and counselling (PITC) be offered as a routine service, 47 and this has been shown to be both feasible and acceptable in various settings. 48, 49 Rates of HIV testing have increased dramatically in the last 5 years, probably as a consequence of the advent of ART. In 2009, over 50% of TB patients in sub-Saharan Africa were tested for HIV. 49 HIV testing establishes the diagnosis of HIV and serves as the gateway to HIV-related prevention and care interventions.
While it is acknowledged that TB patients would merit being screened for DM, 50 51 although its sole use as a diagnostic test is still controversial. 52 Despite its obvious attraction, urine testing for glucose is sub-optimal for early case fi nding of DM at the primary health care level. 53 In high-burden countries, action is already being taken. In Kerala State, India, the Revised National TB Control Programme has already initiated screening of TB patients for DM and is assessing its effect on TB treatment outcomes under routine programme conditions (L S Chauhan, personal communication). A recent stakeholders' meeting in China agreed that a feasible and potentially affordable working strategy would be to screen TB patients at registration and start of anti-tuberculosis treatment by random blood glucose (RBG) tests; if RBG was >6.1 mmol/l, patients could be asked to return at the next visit for a fasting blood glucose (FBG) test; an FBG > 7.0 mmol/l would indicate a diagnosis of DM 54 and the need for referral to DM care for confi rmation of diagnosis and optimal blood glucose management, particularly as blood glucose levels may be elevated in the setting of acute TB infection 50 
PREVENTING AND REDUCING THE BURDEN OF TB IN PLWH AND DM
In PLWH, early initiation of ART through immune reconstitution reduces the risk of TB, 55 and this has led the WHO to recommend that ART should be initiated at CD4 count thresholds of 350 cells/μl rather than 200 cells/μl. 56 Mathematical modelling using the case reproduction number, long-term dynamics of the HIV epidemic, data from South Africa and the known effects of HIV on TB incidence, suggests that a strategy of HIV testing and immediate start of ART could, in a short period of time, signifi cantly reduce the incidence of HIV-associated TB; 23 this approach needs to be evaluated and tested. Further reduction in the risk of TB could be achieved through implementation of the 'Three I's': intensifi ed case fi nding, infection control and INH preventive therapy (IPT). 42 Symptom screening for TB using cough of any duration, weight loss, night sweats and fever now has a sound evidence base for policy recommendations. 57, 58 There are good guidelines on what to do and how to implement TB infection control in health care facilities. 59 The effi cacy of IPT in reducing the risk of active TB in PLWH with latent TB infection has been well established through clinical trials. 60 Evidence has recently shown that 36 months of IPT is more effective than 6 months at reducing the risk of TB among PLWH. 61 What remains now is implementation of policy recommendations in HIV care clinics in high HIV and TB burden countries. In a similar vein, good DM control should reduce the risk of TB, as evidenced by a higher risk of TB in people with poorly controlled DM compared to those with well controlled DM. 26, 27 Although no data are available from recent intervention studies to support the use of IPT, two observational studies conducted in Germany in the 1950s and Russia in the 1960s showed that chemoprophylaxis with either INH or an INH analogue respectively reduced the primary and secondary risk of TB in DM patients. 62, 63 However, the absence of randomisation and the lack of details of the interventions in these two studies limit the evidence base to support IPT in DM patients.
While it is acknowledged that DM patients living in high TB burden countries might merit active screening for TB, 50 experience in routine health settings about how to do this is limited. TB screening should be performed at each visit using a simple symptom screen similar to what has been adopted for intensifi ed case fi nding in PLWH. 58 Screening by chest X-ray could also be considered at the time of DM diagnosis, and possibly at regular intervals thereafter. If screening identifi es a signifi cant number of previously undiagnosed TB cases, the issue of infection control should not be forgotten, and guidelines to prevent nosocomial TB transmission within HIV care facilities should be considered for DM clinics. The concept of the Three I's for PLWH should be considered, adapted and evaluated in DM patients as a way of reducing the dual disease burden.
MONITORING, RECORDING AND REPORTING
Effective collaboration between TB and HIV programmes demands that each reliably monitor and report on one another's parameters. This has been an iterative process, guided by intuition and experience, resulting in a revised international guide that spells out the data required for denominators, numerators and indicators to monitor progress in HIV care in TB patients and TB preventive efforts in PLWH. 64 Treatment cards, registers and cohort reporting forms have required modifi cation and revision to accommodate such collaboration on the ground.
At present little is known on how to conduct such monitoring in DM and TB, and operational research will be needed to test out different modalities. The recent stakeholders' meeting in China agreed on some ways forward (A D Harries and L Yan, personal communication). A register similar to that shown in Figure 1 might be a useful tool to be used alongside the Patient TB Register to monitor DM screening in TB patients, with a template for the cohort reporting shown in Table 2 . A treatment card similar to that shown in Figure 2 might be a useful tool to monitor TB screening in DM patients when they attend the DM clinic, with a template for the cohort reporting shown in Table 3 . These suggested tools need to be piloted and evaluated in fi eld conditions in various settings.
FRAMEWORK FOR COLLABORATION
One of the important milestones in the fi ght against HIV and TB was the publication and dissemination in 2004 of the WHO Interim Policy of Collaborative (Table 4) . 65 As the evidence base for policy recommendations was weak at that time, the guidance was promoted as interim in nature. New evidence and experience has since become available, and as a result the policy has been updated and should be published in 2011.
An important step in the fi ght against DM and TB has been the development of a WHO-Union Framework for Collaborative activities to guide policy makers and implementers in reducing the dual burden of DM and TB (Table 5) . 66 This was developed through an iterative process, 67 with the WHO giving clearance to develop a Framework rather than Guidelines due to lack of strong evidence to support some of the suggested interventions. The Framework was printed in August 2011, 66 and will serve as a guide to help policy makers and implementers move forward to combat the looming epidemic. It will be important to ensure that interventions are delivered within the context of general health systems, that they take into account other chronic non-communicable diseases, and that engagement is sought both with and from civil society.
CONCLUSION
The global and national response to the HIV-associated TB epidemic was slow and uncoordinated. The fi rst reports of the association between HIV/AIDS and TB were published in the late 1980s, 68, 69 and warnings were clearly articulated in the early 1990s about the impending scale of the forthcoming dual Table 2 Quarterly report of diabetes screening in TB patients* Number of TB patients registered Number already known with DM Number screened with RBG Number with RBG > 6.1 mmol/l (110 mg/dl) Number screened with FBG Number with FBG < 6.1 mmol/l (110 mg/dl) Number with FBG 6.1-7.0 mmol/l (110-126 mg/dl) Number with FBG > 7.0 mmol/l (126 mg/dl) Number newly diagnosed with DM (FBG > 7.0 or 126 mg/dl) Number with known DM + number with new DM Number referred to diabetes care Number confi rmed with DM in diabetes clinic and entered to DM care * Quarterly report completed 1 month after end of the quarter. TB = tuberculosis; DM = diabetes mellitus; RBG = random blood glucose; FBG = fasting blood glucose. epidemic. 70, 71 Little action was taken, and HIV and TB programmes barely interacted at global, national or district levels. It was not until 2004, with the release of the WHO interim policy, 42 that collaborative HIV and TB activities got under way and progress was made in the fi ght against the two diseases. We cannot afford to make the same mistake with DM and TB.
In low-and middle-income countries, the DM epidemic is growing quickly. In sub-Saharan Africa, the absolute numbers of DM patients are predicted to grow from 12 million in 2010 to 24 million by 2030, with most cases undiagnosed and untreated. 72 However, it is Asia, as we have said earlier, that will bear the brunt of this epidemic, with the number of DM patients in South-East Asia and the Western Pacifi c predicted to reach over 210 million by 2030. 14 Epidemiological models using 2000 data in India have already shown the important interaction between DM and TB in that country, with DM accounting for 20% of smear-positive pulmonary TB cases, 73 and recent analyses have indicated that the increase in DM prevalence in India has been a signifi cant impediment to reducing TB incidence in that country. 21 We must learn from the TB-HIV epidemic. One of the important keys to controlling the TB-HIV epidemic lies in preventing new HIV infections, and a milestone in this regard has been the recent recognition of the important TB preventive role of ART. 42 With a global DM epidemic that is escalating rapidly, the prevention and control of DM is likely to be an equally important intervention in controlling the DM-TB epidemic. Primary prevention of DM through attention to unhealthy diets, sedentary lifestyles and childhood and adult obesity must be included in broad prevention strategies for non-communicable diseases. Better integration of communicable and noncommunicable disease prevention and care strategies that are focused on the patient rather than the disease is required. As with TB-HIV, we must adapt and apply similar methods of preventing, screening and treating the two diseases together, and ensure that we have secure pipelines for drugs, that we develop mechanisms of working together, that we undertake relevant operational and other kinds of research, 36 and that we adopt the philosophy of 'learning by doing'. We may then stand a good chance of winning this war. La prevalencia de diabetes sacarina aumenta a un ritmo alarmante y algunos países de Asia, en especial la India y China, soportarán la mayor carga de esta epidemia. Las personas diabéticas presentan un riesgo de padecer tuberculosis (TB) activa que es dos a tres veces más alto que el riesgo de las personas sin diabetes. En el presente artículo se propone que las interacciones epidemioló-gicas y clínicas con respecto al modo de presentación y al tratamiento son equivalentes a las interacciones que se han observado en la coinfección por el virus de la i nmunodeficiencia humana (VIH) y la TB. Las lecciones extraídas de las estrategias encaminadas a disminuir la carga de morbilidad por esas dos enfermedades, sobre todo en materia de métodos de detección sistemática, se pueden aplicar a la detección, el diagnóstico, el tratamiento y la prevención de la diabetes y la TB. El nuevo marco de acción conjunta para la atención y el control de la TB y la diabetes de La Unión y la Organización Mundial de la Salud (OMS) muestra muchas similitudes con la política de la OMS sobre las actividades de colaboración que tienden a aliviar la carga de morbilidad por TB e infección por el VIH; el marco tiene como objetivo guiar a las instancias normativas y ejecutoras en el progreso de la lucha contra esta inminente epidemia doble. En los años 1980 y 1990, la respuesta a la epidemia progresiva de coinfección por el VIH y la TB fue lenta y des coordinada, pese a las alertas que se expresaron claramente sobre la amplitud del problema que se acercaba. No se debe cometer el mismo error con la diabetes y la TB. Este marco ofrece un modelo para la acción y es ahora responsabilidad de los donantes y las instancias normativas y ejecutoras que se apliquen las recomendaciones en el terreno y 'se aprenda actuando'.
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